药物信息为Femring (estradiol acetate vaginal ring) (Warner Chilcott (US), LLC): CONTRAINDICATIONS
- WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA FOR ESTROGEN-ALONE THERAPY
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- ADVERSE REACTIONS
- OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- STORAGE
- PATIENT INFORMATION
- TRADE CARTON - Femring 0.05 mg
- SAMPLE CARTON - Femring 0.05 mg
- TRADE CARTON - Femring 0.10 mg
- SAMPLE CARTON - Femring 0.10 mg
- 外部链接相关的Femring (estradiol acetate vaginal ring) (Warner Chilcott (US), LLC)
Femring should not be used in women with any of the following conditions:
- Undiagnosed abnormal genital bleeding.
- Known, suspected, or history of breast cancer.
- Known or suspected estrogen-dependent neoplasia.
- Active deep vein thrombosis, pulmonary embolism or history of these conditions.
- Active arterial thromboembolic disease (for example, stroke and myocardial infarction) or a history of these conditions.
- Known liver dysfunction or disease.
- Known or suspected pregnancy.
- Drug Information Provided by National Library of Medicine (NLM).
